Financings in Brief: Angeion
This article was originally published in The Gray Sheet
Executive Summary
Angeion: Files registration statement with Securities and Exchange Commission for a direct placement, principally to selected institutional investors, of 2.5 mil. shares of common stock. Proceeds will go toward R&D, clinical trials, capital equipment, leasehold improvements and general corporate purposes, the Minneapolis-based firm says. Stock in Angeion has recently been trading in the $4-6 range. The firm is developing the Sentinel implantable cardioverter defibrillator and catheter ablation systems. The offering follows a direct placement of 4.9 mil. securities last fall ("The Gray Sheet" Oct. 10, 1994, p. 20). Raymond James & Associates is placement agent for the offering...